At Royds Withy King we are still able to serve all your legal needs during the Coronavirus pandemic. Find out more.

Search articles

3 July 2020 0 Comments Posted in Corporate, Opinion

Covid-19: a new landscape for business valuations

Author headshot imagePosted by , Partner

EBITDAC

EBITDAC is the new acronym which has been much discussed recently as businesses and their advisers get to grips with how to adjust valuations to take into account the impact of Covid-19. Does this further increase uncertainty in an already unsettled M&A market and how much are we really going to see it used?

Read more

16 June 2020 0 Comments Posted in Corporate, Uncategorized

Private equity and Covid-19: the drive towards recovery

Author headshot imagePosted by , Partner

There has been a lot for private equity (PE) funders to deal with in the wake of the Covid-19 pandemic. Understandably short-term focus has been on supporting existing portfolio companies, but the expertise and resilience of PE funders (and their advisers) combined with a strong appetite to do deals means that PE-backed buy-outs and bolt-on acquisitions are likely to have a central role in the drive towards recovery.

Read more

7 May 2020 0 Comments Posted in Corporate & Commercial, News

Royds Withy King helps Oxford Genetics secure a further £3.0m syndicated investment

Author headshot imagePosted by , Partner

Royds Withy King is pleased to announce that it’s helped Oxford Genetics (trading as OXGENE™), based at the Oxford Science Park, with a further £3.0m syndicated investment committed by Mercia Asset Management and Canaccord Genuity Wealth Management.

Read more

6 April 2020 0 Comments Posted in Corporate, Opinion

Oxford Genetics joins the coronavirus testing effort

Author headshot imagePosted by , Partner

Oxford genetics

Testing is currently on top of the Government’s agenda in its efforts to slow down the coronavirus pandemic.

The spotlight is now very much on the UK’s life sciences sector and we’re very proud that our client Oxford Genetics (trading as OXGENE) has formed a strategic partnership with The Native Antigen Company Limited (NAC), another portfolio company backed by Mercia Asset Management, to scale up production of Covid-19 antigens to test for the disease.

Read more

25 March 2020 0 Comments Posted in Commercial, Corporate, Opinion

Business alert: Companies House extends accounts filing deadline

Author headshot imagePosted by , Partner

Companies House

Companies House have updated their policy so that if accounts are not able to be filed on time due to the company being affected by Coronavirus, the company may make an application before their deadline to extend the period allowed for filing. Upon application, the company will receive an automatic and immediate 3 month extension to file their accounts.

Read more

Is Entrepreneurs’ Relief really ‘at risk’? What to expect from today’s budget…

Author headshot imagePosted by , Partner

The issue of whether entrepreneurs’ relief (ER) will be scrapped in the Budget remains on the agenda, but you need to act now, says Iain Butler, a Corporate Partner in our Private Wealth team.

Read more

31 October 2019 0 Comments Posted in Corporate, Corporate & Commercial, Opinion

A guide to parent companies and their subsidiaries: how far does responsibility go?

Author headshot imagePosted by , Partner

We are often used to hearing sayings like “the apple doesn’t fall far from the tree” or “like father like son/like mother like daughter”. These phrases are casually used to suggest that a child’s actions are not far off from the actions of their parent, or that a parent is wholly responsible for the behaviour of their child.

Read more

1 April 2019 0 Comments Posted in Corporate & Commercial, News

Royds Withy King helps Oxford Genetics to secure £6.5m funding deal

Author headshot imagePosted by , Partner

Corporate lawyers from Royds Withy King have helped Oxford Genetics, an Oxford based biotechnology business which specialises in biological drug development, to secure a £6.5m syndicated investment which will further secure its position as a market-leading innovator of synthetic biology-based technologies. The cash injection values Oxford Genetics, which is based at Oxford Science Park, at £30.5m.

Read more

11 December 2018 0 Comments Posted in Corporate & Commercial, News

Corporate team supports Oxford Sciences Innovation (OSI) investment in Oxford University spin out and the management team of DNA testing business

Author headshot imagePosted by , Partner

Ian Butler press release

Over the last five months, the Oxford based Corporate team at Royds Withy King has successfully completed a number of transactions, particularly in the life sciences and technology sectors. The team, led by Iain Butler, successfully advised Edtopia Limited, a …

Read more

28 August 2018 0 Comments Posted in Corporate & Commercial, News

Royds Withy King advises on the MBO of Argosy Components

Author headshot imagePosted by , Partner

Press release

Royds Withy King’s Corporate team in Oxford have acted for the management team of Argosy Components Ltd on the management buyout of the company. Founded in 1984 and based in Long Crendon, Oxfordshire, Argosy Components serves the broadcast and communication …

Read more

16 July 2018 0 Comments Posted in News

Oxford lawyers scoop Law Society awards

Author headshot imagePosted by , Partner

Two lawyers from Royds Withy King in Oxford have come out on top at the prestigious Berks, Bucks and Oxfordshire Law Society Awards 2018. Jennifer Sampson, a lawyer in the Corporate team at Royds Withy King, was named Junior Lawyer …

Read more

23 March 2018 0 Comments Posted in Opinion

A Post-Brexit UK: It’s not all about blue passports, is it…?

Author headshot imagePosted by , Partner

We are in the thick of a period of economic and business uncertainty during which the terms of the UK’s exit from the EU remain to be agreed.  Brexit has already led to volatility in the financial markets and businesses …

Read more

Search articles